 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...132133134135136137138139140141142143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Cetuximab and Carbo for ER/PR/HER2 Negative BC (clinicaltrials.gov) - Aug 2, 2012
P2, N=11, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed
- ||||| duligotuzumab (MEHD7945A) / Roche
New P2 trial, Metastases: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Jul 26, 2012
P2, N=135, Active, not recruiting, Sponsor: Genentech
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Metastases: Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas (clinicaltrials.gov) - Jul 23, 2012
P2, N=36, Completed, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed Initiation date: Mar 2005 --> Jun 2005
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Reduced-intensity Therapy for Advanced Oropharyngeal Cancer in Non-smoking Human Papilloma Virus (HPV)-16 Positive Patients (clinicaltrials.gov) - Jul 23, 2012
P2, N=36, Active, not recruiting, Sponsor: University of Michigan Cancer Center
- |||| Gilotrif (afatinib) / Boehringer Ingelheim
Trial completion, Metastases: BIBW 2992 (Afatinib) in Head & Neck Cancer (clinicaltrials.gov) - Jul 23, 2012
P2, N=124, Completed, Sponsor: Boehringer Ingelheim
Initiation date: Mar 2005 --> Jun 2005 Active, not recruiting --> Completed
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
P4 data, Enrollment change, Metastases: EMR62241-508: Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea (clinicaltrials.gov) - Jul 19, 2012
P=N/A, N=300, Recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed N=600 --> 300
- | tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Enrollment change: An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols (clinicaltrials.gov) - Jul 19, 2012
P1/2, N=50, Recruiting, Sponsor: ArQule
N=600 --> 300 N=30 --> 50
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Metastases: Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer (clinicaltrials.gov) - Jul 19, 2012
P=N/A, N=100, Recruiting, Sponsor: Centre Oscar Lambret
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Surgery: NCCTG N0147: Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer (clinicaltrials.gov) - Jul 18, 2012
P3, N=3768, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 50 Completed --> Active, not recruiting
- Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial suspension, Metastases: Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy (clinicaltrials.gov) - Jul 17, 2012
P2, N=147, Suspended, Sponsor: Eastern Cooperative Oncology Group
Completed --> Active, not recruiting Recruiting --> Suspended
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P1 trial, Combination therapy, PARP Biomarker, Metastases: Olaparib With Cetuximab & Radiation Therapy in Head & Neck Squamous Cell Carcinomas in Patients With Smoking Histories (clinicaltrials.gov) - Jul 17, 2012
P1, N=24, Recruiting, Sponsor: University of Colorado, Denver
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer (clinicaltrials.gov) - Jul 17, 2012
P2, N=38, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Suspended Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions (clinicaltrials.gov) - Jul 15, 2012
P2, N=40, Completed, Sponsor: Asan Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination: EMMA-1 (Erbitux for Multiple Myeloma) (clinicaltrials.gov) - Jul 11, 2012
P2, N=13, Terminated, Sponsor: Prof. Dr. Andreas Engert
Active, not recruiting --> Completed Recruiting --> Terminated; Lack of recruitable patients
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: EMMA-1 (Erbitux for Multiple Myeloma) (clinicaltrials.gov) - Jul 11, 2012
P2, N=13, Terminated, Sponsor: Prof. Dr. Andreas Engert
Recruiting --> Terminated; Lack of recruitable patients N=33 --> 13
- ||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Circulating tumor cells, Tumor cell, Metastases: VISNU-2: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (clinicaltrials.gov) - Jul 11, 2012
P2, N=240, Recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer (clinicaltrials.gov) - Jul 10, 2012
P2, N=83, Active, not recruiting, Sponsor: Eastern Cooperative Oncology Group
N=33 --> 13 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial, Metastases: Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer (clinicaltrials.gov) - Jul 9, 2012
P1, N=12, Completed, Sponsor: Fox Chase Cancer Center
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Jul 2, 2012
P2, N=48, Completed, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Combination therapy, Metastases: Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC (clinicaltrials.gov) - Jun 27, 2012
P=N/A, N=20, Not yet recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: DEBIRITUX: TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer (clinicaltrials.gov) - Jun 26, 2012
P2, N=8, Terminated, Sponsor: Martin-Luther-Universit
Active, not recruiting --> Completed Recruiting --> Terminated; Terminated due to poor subject enrolment
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: DEBIRITUX: TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer (clinicaltrials.gov) - Jun 26, 2012
P2, N=8, Terminated, Sponsor: Martin-Luther-Universit
Recruiting --> Terminated; Terminated due to poor subject enrolment N=80 --> 8
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer (clinicaltrials.gov) - Jun 26, 2012
P2, N=15, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
N=80 --> 8 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Combination therapy: Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project (clinicaltrials.gov) - Jun 24, 2012
P=N/A, N=21, Terminated, Sponsor: Universitaire Ziekenhuizen Leuven
Not yet recruiting --> Recruiting Recruiting --> Terminated; Lack of recruitment
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy: Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project (clinicaltrials.gov) - Jun 24, 2012
P=N/A, N=21, Terminated, Sponsor: Universitaire Ziekenhuizen Leuven
Recruiting --> Terminated; Lack of recruitment N=80 --> 21
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: SAKK 08/07: Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Jun 23, 2012
P2, N=35, Completed, Sponsor: Swiss Group for Clinical Cancer Research
N=80 --> 21 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Combination therapy: Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0 (clinicaltrials.gov) - Jun 18, 2012
P1, N=21, Recruiting, Sponsor: Lund University Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer (clinicaltrials.gov) - Jun 16, 2012
P2, N=73, Completed, Sponsor: North Central Cancer Treatment Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial, Combination therapy: Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0 (clinicaltrials.gov) - Jun 14, 2012
P1, N=21, Recruiting, Sponsor: Lund University Hospital
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes (clinicaltrials.gov) - Jun 13, 2012
P2, N=31, Active, not recruiting, Sponsor: UNICANCER
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Combination therapy, Metastases: Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin (clinicaltrials.gov) - Jun 11, 2012
P2, N=150, Completed, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Active, not recruiting --> Completed N=100 --> 150
- |||| cixutumumab (IMC A12) / Eli Lilly, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before (clinicaltrials.gov) - Jun 11, 2012
P2, N=64, Completed, Sponsor: ImClone LLC
N=100 --> 150 Active, not recruiting --> Completed
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin (clinicaltrials.gov) - Jun 11, 2012
P2, N=150, Completed, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Surgery, Metastases: SAKK 75/06: Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Jun 7, 2012
P1/2, N=27, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer (clinicaltrials.gov) - Jun 6, 2012
P2, N=46, Active, not recruiting, Sponsor: Fudan University
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Individualized Drug Treatment for Treating Patients With Pancreatic Cancer (clinicaltrials.gov) - Jun 5, 2012
P2, N=85, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed N=40 --> 85
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial, Combination therapy, Metastases: Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer (clinicaltrials.gov) - Jun 3, 2012
P1/2, N=1, Terminated, Sponsor: Dr Anna Dorothea Wagner
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Surgery, Metastases: SAKK 41/04: Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 3, 2012
P2, N=74, Completed, Sponsor: Swiss Group for Clinical Cancer Research
N=40 --> 85 Active, not recruiting --> Completed
- ||||| dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
New P2a trial, Combination therapy, Metastases: A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) (clinicaltrials.gov) - May 29, 2012
P2a, N=70, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: EXPAND: Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer (clinicaltrials.gov) - May 29, 2012
P3, N=904, Completed, Sponsor: Merck KGaA
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Piqray (alpelisib) / Novartis
New P2 trial, Combination therapy, Metastases: A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - May 16, 2012
P2, N=186, Recruiting, Sponsor: Novartis Pharmaceuticals
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 7, 2012
P1/2, N=64, Active, not recruiting, Sponsor: University of California, Davis
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1/2 trial, Metastases: Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - May 3, 2012
P1/2, N=42, Recruiting, Sponsor: Ahmad Wehbe
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: A Trial of Chemo & Radiation Therapy for Pancreatic Cancer (clinicaltrials.gov) - May 2, 2012
P2, N=8, Active, not recruiting, Sponsor: University of Massachusetts, Worcester
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - May 2, 2012
P1, N=19, Completed, Sponsor: Novartis Pharmaceuticals
Completed --> Active, not recruiting Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Apr 29, 2012
P2, N=33, Recruiting, Sponsor: Ahmad Wehbe
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opaxio (paclitaxel poliglumex) / SOBI
Enrollment open, Metastases: A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer (clinicaltrials.gov) - Apr 19, 2012
P1/2, N=60, Recruiting, Sponsor: State University of New York - Upstate Medical University
Active, not recruiting --> Completed Suspended --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer (clinicaltrials.gov) - Apr 18, 2012
P2, N=15, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
- |||| Zelboraf (vemurafenib) / Roche
Enrollment open: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers (clinicaltrials.gov) - Apr 17, 2012
P2, N=160, Recruiting, Sponsor: Hoffmann-La Roche
Suspended --> Recruiting Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Apr 16, 2012
P1/2, N=42, Recruiting, Sponsor: Jennifer Rubin Grandis
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting